Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...
BioSpace

Compass’ Psychedelic Shows Durability ‘In Spades’ as Path to FDA Clears

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

Why did Compass Pathways stock rocket higher today?

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.
Seeking Alpha

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful ...